Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Eisai to Quit Generic Supply Biz, Transfer Subsidiary to Nichi-Iko
Eisai will bow out of the generic supply business by transferring the entire stake in its wholly owned subsidiary, Elmed Eisai, to leading Japanese generic maker Nichi-Iko Pharmaceutical for roughly 17.12 billion yen, with the transaction expected to be completed…
To read the full story
Related Article
- Nichi-Iko to Leverage Synergies of Integration with Elmed Eisai: Sales Head
April 22, 2019
- Nichi-Iko Takes Full Control of Eisai Generic Arm, Now Renamed “Elmed”
April 2, 2019
- Nichi-Iko to Copromote 5 Elmed Eisai Products from October
September 18, 2018
- Nichi-Iko, Eisai to Copromote Partner’s Generics from October
May 16, 2018
- Nichi-Iko to Raise 21.2 Billion Yen for Elmed Eisai Buyout
April 5, 2018
- Eisai’s Nichi-Iko Deal Marks Watershed in Generic Biz of Research-Driven Makers
April 3, 2018
- Alliance with Nichi-Iko “Not Due to Pessimism about Generic Drug Business,” Will Expand Lineup: Eisai CEO
March 30, 2018
BUSINESS
- Rhythm Pharma Gears Up for First Japan Launch with 50-Strong Team
July 21, 2026
- Fujifilm Toyama Chemical Forms 1st Product-Dedicated Unit for Savyscus
July 21, 2026
- Meiji’s Hiyasta Earns Approval in Thailand
July 21, 2026
- US FDA Accepts Shionogi’s Pediatric Fetroja Filing
July 21, 2026
- Kaken’s Vascular Malformation Drug Shows Efficacy in Japan PIII
July 21, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…